Last updated: February 15, 2026
What is the current market landscape for NDC 70700-0273?
NDC 70700-0273 refers to Tucatinib, a tyrosine kinase inhibitor marketed by Seattle Genetics under the brand name Tukysa. Approved by the FDA in April 2020 for treatment of adult patients with HER2-positive metastatic breast cancer, Tukysa targets systemic HER2-positive cancers regardless of prior treatments.
Market status: As of 2023, Tukysa's revenue growth reflects expanding indications and increasing adoption. Global sales reached approximately $250 million in 2022, with projections indicating continued growth driven by new approvals and expanded clinical trial data.
How does the market size for HER2-positive metastatic breast cancer drugs look?
The global HER2-positive metastatic breast cancer therapeutics segment was valued at roughly $7.5 billion in 2022. It is expected to grow at a compound annual growth rate (CAGR) of 8% through 2030, influenced by:
- Rising incidence of breast cancer globally [1].
- Increased adoption of targeted therapies like Tucatinib.
- Expansion of approved indications.
Key competitors include trastuzumab (Herceptin), pertuzumab (Perjeta), trastuzumab emtansine (Kadcyla), and neratinib (Nerlynx). Tucatinib's niche is its efficacy in brain metastases, giving it a competitive advantage.
What are the price points and reimbursement landscape?
List price: The wholesale acquisition cost (WAC) for Tukysa is approximately $27,300 per month, amounting to about $327,600 annually (as of 2023). This aligns with other targeted oncology drugs but remains subject to payor negotiations.
Reimbursement status: Medicare, Medicaid, and commercial insurers cover Tukysa, contingent on patient eligibility and prior authorization. The high price influences access, with price reductions often required for formularies prioritization.
What are future price projections?
Price projections for Tukysa depend on regulatory, market, and competitive dynamics:
-
Stable pricing scenario: Maintaining current price levels, revenue is expected to grow with increased adoption. Sales projections estimate $350-400 million in 2025, contingent on approval of expanded indications.
-
Price reduction scenario: Negotiation-driven discounts, typical for targeted medicines, could lower prices by 10-20%. This compression would affect revenue growth, lowering projected sales for 2025 to roughly $300 million.
Potential for biosimilar entry or alternative treatments remains limited due to Tukysa's unique indication profile and ongoing clinical trials.
What is the outlook on regulatory and market expansion?
Additional approvals, especially for earlier lines of therapy or other HER2-positive cancers, could extend the market. Seattle Genetics has ongoing trials in combination with other agents and in different tumor types.
The U.S. FDA granted Breakthrough Therapy designation for Tukysa in certain settings, which could expedite approval timelines for new indications.
Summary of key points:
- Current annual sales (2022): ~$250 million.
- Price per month: Approx. $27,300; annual: ~$327,600.
- Growth drivers include expanding indications and improved efficacy in brain metastases.
- Future revenue depends heavily on approval expansion and market penetration.
- Pricing remains high with potential for negotiated discounts or rebates.
Key Takeaways
- NDC 70700-0273 (Tucatinib) generates significant market revenue in HER2-positive breast cancer.
- The market is growing, driven by clinical advantages in managing brain metastases and expanding indications.
- Price points are high but subject to payor negotiations and potential discounts.
- Revenue projections through 2025 reach $300-400 million, depending on regulatory and competitive factors.
- Market expansion remains probable as clinical evidence supports broader use.
FAQs
Q1: How does Tucatinib compare price-wise to other HER2 targeted therapies?
Tucatinib’s monthly cost is comparable or slightly higher than similar agents like Nerlynx ($18,000/month). Its unique efficacy in brain metastases justifies the premium.
Q2: Are there upcoming patent expirations that could impact pricing?
Patents for Tucatinib are expected to extend into early 2030s. No generic competition is imminent within the next 2-3 years.
Q3: What are the primary drivers for future revenue growth?
Expansion of indications, inclusion in earlier lines of therapy, and favorable clinical trial outcomes are principal growth drivers.
Q4: How do reimbursement policies influence market access?
Reimbursement depends on insurer policies, clinical evidence, and negotiated discounts; high drug price can limit access for some patient populations.
Q5: What risks could impact future market projections?
Regulatory setbacks, clinical trial failures, or competitive pipeline intrusions pose risks to growth and pricing strategies.
Sources
[1] GlobalData, “Breast Cancer Therapeutics Market Analysis,” 2023.
